On July 30, Madrigal Pharmaceuticals declined 12.78% in regular trading, trading at $476.98/share, with turnover of $347 million. The sell-off was triggered by the company's Q2 earnings report released pre-market, where revenue beat but widening losses sparked investor concerns over profitability trajectory.

Specifically, Q2 product revenue reached $364.3 million, exceeding the consensus estimate of $353 million, while EPS loss of $1.99 beat the analyst estimate of $2.50. Core product Rezdiffra delivered net sales growth of 71% year-over-year, with over 49,000 patients on therapy, more than doubling from the prior-year period. However, EPS loss widened 4.74% from $1.90 a year earlier, with net loss totaling $57.9 million. Despite strong commercial momentum, the market's divergence over the pace of profitability improvement drove sustained selling pressure from pre-market through the regular session. The company reported cash and marketable securities of $838.9 million as of June 30.

Within the Biotechnology sector, weakness was broad-based, with Alnylam Pharmaceuticals down 27.08%, AbbVie down 2.94%, and Gilead Sciences down 2.84%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)